Medical device software quality has a reputation problem. To many early-stage teams, it sounds like overhead, a set of procedures that slow the real work of building and shipping.
After years of building software in environments that have to move quickly and still stand up to clinical, regulatory, and investor scrutiny, I have come to see it the other way around. Quality, introduced early and at the right level for the company’s stage, is one of the things that keeps a startup moving forward. The idea worth holding onto is quality as a forcing function.
This article lays out why, through four ideas: why startup momentum is fragile, the difference between working and milestone-ready software, why every milestone becomes an evidence conversation, and how to shift the thinking left without drowning a young company in process.
What is Quality as a Forcing Function
Quality forces clarity: about what the team is building, why, which risks matter, how the team knows the software works, and what the company will need to show at its next milestone. When those questions are answered while the work is happening, rather than reconstructed afterward, the result is a stronger path to safety, speed, and lower cost.
Startup momentum is fragile
Early-stage MedTech teams do an enormous amount with limited runway and limited people, on a product that is still evolving. Because every financing round, study, pilot, and partnership can change the company’s future, the instinct is to sprint toward the next visible milestone.
That instinct is understandable, and early companies should not carry the overhead of big companies. But the work a team does today either moves the company forward or creates work it will have to repeat.
A team can feel fast while quietly accumulating documentation debt, the kind that sends companies backward later. Stage-appropriate quality is a momentum strategy precisely because it helps a company avoid spending scarce time and capital fixing problems that the right process would have prevented.
Working software is not milestone-ready software
One of the most useful distinctions for a startup is between working software and milestone-ready software. Working software means the demo runs, the device connects, the code behaves as expected, and the team is learning quickly. That is valuable, and in early development it may be exactly what the company needs.
Milestone-ready software has to do more than function. It has to be understandable and reviewable by people who were not part of the daily build. The intended use is clear for the stage of development; risks are identified and tied to controls; tests trace to requirements; and the specific version of the software and its supporting evidence are controlled.
Teams get surprised here because a team can be completely correct that the software works while a clinician, reviewer, hospital partner, or acquirer still says the product is not ready. Working is an engineering statement. Ready is a clinical, regulatory, and commercial statement, and the distance between the two is where startups lose time.
This is also where medical device software documentation earns its keep. In a regulated product, documentation is the evidence of quality, the development record that lets someone outside the daily build understand and trust the decisions the team made. It is most accurate and useful when created alongside the code rather than reconstructed later. For software that meets the definition of a medical device, that evidence discipline is what the Software as a Medical Device lifecycle depends on.
Every milestone becomes an evidence conversation
As a company moves forward, the questions change, but the need to show the work stays the same. Early study work asks about the software version, the relevant risks, and the testing behind them. Clinical work expands into configuration, data integrity, and consistent behavior in the real environment.
Regulatory review makes the evidence explicit: traceability, verification and validation, risk controls, cybersecurity, and change history become the formal story of the product. Commercial launch adds controlled releases, supportability, security, and audit trails. And when a company raises money or prepares for an acquisition, investors and acquirers assess hidden risks, including whether the software can be inherited, supported, and commercialized without a heavy remediation burden.
Quality, in other words, is not only a regulatory concern. It reduces uncertainty for every stakeholder who eventually relies on the product, and lower uncertainty is one way quality helps commercialization move faster.
The remediation loop, and how to avoid it
The cautionary version of this story is medical device software remediation. Software often begins as a prototype, a research tool, or a general build, and later needs to support a regulated milestone. The team says the software already exists and only the documentation is missing. But when the milestone asks for evidence, the work becomes a remediation effort: reconstructing requirements, establishing traceability, repeating or strengthening testing, recreating documentation, and closing validation gaps that were invisible when the only question was whether the software ran.
Remediation is not impossible, and sometimes it is exactly what must happen. The problem is that it sends time and money into the past instead of toward the next milestone. Instead of using engineering capacity to move the product forward, the company pays people to recreate the story of decisions already made, and in software, that is especially costly, because code changes quickly and evidence drifts away from the product fast.
Shift left, at the right size for the stage
The practical answer is to shift the thinking left, understood correctly in the context of a startup. It does not mean pulling every regulatory deliverable into the earliest stage, nor does it mean a large-company quality burden before the product is proven.
It means bringing the right questions into the development workflow early enough that the answers can still shape the software. Intended use, requirements, risk, build and test, evidence, and milestone planning stay connected, so that when the software changes, the related requirements, risks, tests, and documentation move with it. That is the practical link between continuous delivery and continuous compliance.
Quality does not speed up commercialization by eliminating the work. It speeds it up by helping a team do the work once, at the right time, in a way that carries forward. The fastest path is usually the one with the fewest preventable detours. It is the same principle behind purpose-built, regulatory-ready infrastructure like the NEX platform: start on a foundation where software and evidence already move together, and the next milestone becomes a forward step rather than a remediation project.
Sequenex builds medical-device software where code and documentation develop together under an ISO 13485-certified quality management system. The perspective here comes from doing that work alongside teams that need to move quickly while still standing up to scrutiny. To discuss how it applies to your product, get in touch.
